神経血管デバイス市場規模、シェア、動向、2030年までの世界予測

世界の神経血管デバイス市場は、2025年の46億4000万米ドルから2030年には72億2000万米ドルに達するとMarketsandMarketsでは予測されており、予測期間中の年平均成長率は9.3%となる見込みです。

高齢化、高血圧、喫煙、運動不足といった要因により、神経血管疾患の罹患率が上昇しており、効果的なモニタリングと治療のための高度なツールの需要が著しく高まっています。脳卒中、脳動脈瘤、動静脈奇形などの疾患の発生率が増加するにつれ、タイムリーな診断と低侵襲治療の必要性も高まっています。これらの疾患のリスクが高い高齢者人口の増加は、神経血管デバイスへの需要をさらに押し上げています。技術革新により、これらのデバイスはより効率的で正確になり、医療従事者と患者の両方にとって魅力的なものとなっています。

調査概要

本レポートは、神経血管デバイス市場の分析を提供します。疾患の種類、エンドユーザー、地域など、さまざまなセグメントにおける市場規模と将来の成長可能性の推定に焦点を当てています。また、主要市場プレーヤーの競合分析も含まれており、各社の企業概要、製品・サービス、最近の動向、主要な市場戦略を詳しく解説しています。

本レポートを購入する理由

本レポートは、糖尿病治療デバイス業界の市場リーダーと新規参入企業の両方にとって貴重な情報を提供します。市場全体および各サブセグメントの推定収益額などが含まれています。関係者は競争環境を理解し、自社の事業をより効果的に位置づけ、効果的な市場参入戦略を策定することができます。さらに、本レポートは主要な市場推進要因、阻害要因、課題、機会を明らかにし、関係者が市場の現状を評価するのに役立ちます。

本レポートは、以下のポイントに関する洞察を提供します。

主要な推進要因（神経血管疾患の罹患率の上昇、神経血管手術に対する医療費償還制度の整備、新興国における医療インフラの拡大、効果的な神経血管治療への需要の高まり）、阻害要因（熟練した脳神経外科医の不足、神経血管手術および関連製品の高額な費用）、機会（次世代神経介入のためのAIおよびロボット支援システムの進歩、低侵襲神経外科手術への嗜好の高まり）、そして課題（医療機器に対する厳格な規制承認プロセス）の分析。

• 市場浸透度：世界の神経血管デバイス市場における主要企業の製品ポートフォリオに関する詳細な情報を提供します。本レポートは、疾患病理、エンドユーザー、地域など、様々なセグメントを網羅しています。
• 製品強化／イノベーション：世界の神経血管デバイス市場における新製品の発売と予測されるトレンドに関する包括的な詳細情報。
• 市場開発：疾患病理、エンドユーザー、地域別に、収益性の高い成長市場に関する徹底的な知識と分析を提供します。
• 市場の多様化：世界の神経血管デバイス市場における、新製品・サービス、拡大市場、最新の技術進歩、投資に関する包括的な情報を提供します。
• 競合評価：世界の神経血管デバイス市場における主要競合企業の市場シェア、成長戦略、製品・サービスの提供内容、能力を徹底的に評価します。

Report Description

The global neurovascular devices market is projected to reach USD 7.22 billion in 2030 from USD 4.64 billion in 2025, at a CAGR of 9.3 % during the forecast period.

The rising prevalence of neurovascular diseases, driven by factors like aging populations, hypertension, smoking, and sedentary lifestyles, is significantly increasing the demand for advanced tools for effective monitoring and treatment. As the incidence of conditions such as stroke, brain aneurysms, and arteriovenous malformations grows, so does the need for timely diagnosis and minimally invasive procedures. The expanding elderly population, which faces higher risks for these conditions, further drives the demand for neurovascular devices. Technological innovations are enhancing these devices to be more efficient, accurate, and appealing to both healthcare professionals and patients.

However, wider adoption of these solutions may be limited by high treatment costs, a shortage of skilled neurosurgeons, and a strict regulatory approval process for medical devices.

Based on disease pathology, the cerebral aneurysm segment is expected to account for the largest share of the global neurovascular devices market.

Based on disease pathology, the global neurovascular devices market is divided into five main segments: cerebral aneurysms, ischemic strokes, carotid artery stenosis, arteriovenous malformation & fistulas, and other disease pathologies. The cerebral aneurysms segment held the largest share of the market. The high occurrence of cerebral aneurysms results from lifestyle, physiological, and genetic factors. Chronic hypertension, smoking, and atherosclerosis greatly weaken blood vessel walls, while habits like alcohol intake and a sedentary lifestyle increase vascular stress. Age and gender also play a role, with middle-aged individuals and women facing higher risks. Furthermore, those with a family history of aneurysms or certain genetic disorders are more likely to develop these conditions, making genetics a key underlying factor.

Based on end user, the hospitals & ambulatory surgical centres segment is expected to account for the largest share of the global neurovascular devices market.

Based on end user, the global neurovascular devices market is segmented by end user into the following categories: hospitals & ambulatory surgical centres, specialty clinics, research and academic institutes. Among these, the hospital and ambulatory surgical center segment is expected to capture the largest market share. They have the latest diagnostic tools and experienced, well-trained medical teams to handle critical conditions like strokes, aneurysms, and vascular malformations. Hospitals and surgical centers provide fast, specialized care, which is often essential in time-sensitive situations. Their ability to offer continuous monitoring, rehabilitation services, and manage complications ensures optimal patient outcomes, which is the main reason for their leading position in the market landscape.

The Asia Pacific is expected to grow at the highest CAGR in the neurovascular devices market during the forecast period.

The rapid rise in neurovascular disease cases and the increasing demand for advanced treatments are driving high demand for neurovascular devices in the Asia Pacific region. Additionally, global leaders in neurovascular devices are expanding their presence in APAC by introducing advanced formulations to develop robotic systems that enhance patient outcomes in complex hemorrhagic cases and urgent ischemic issues, as well as strokes.

A breakdown of the primary participants (supply side) for the neurovascular devices market referred to in this report is provided below:

• By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%)
• By Designation: C-level Executives (20%), Directors (35%), and Others (45%)
• By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (20%), Middle East & Africa (2%), GCC Countries (3%)

Prominent players in the diabetes care devices market include Stryker (US), Medtronic (Ireland), Johnson & Johnson (US), Terumo Corporation (Japan), Penumbra (US), MicroPort Scientific Corporation (China), Balt Group (France), Kaneka Corporation (Japan), Phenox GmbH (Wallaby Medical), Asahi Intecc Co., Ltd (Japan), Achieva Medical (Peijia Medical) (China), Rapid Medical (Israel), Japan Lifeline (Japan), Acandis GmbH (Germany), Evasc Medical System Corp (Canada), Sensome (France), Lepu Medical Technology (Beijing) Co., Ltd (China), Imperative Care, Inc. (US), Medikit Co., Ltd (Japan), Zylox-Tonbridge Medical Co., Ltd (China), Neurosafe Medical Co., Ltd (China), Luseed Vascular (Israel), NeuroVasc Technologies, Inc. (US), Oxford Endovascular (UK), and Galaxy Therapeutics (US).

Research Coverage

The report provides an analysis of the neurovascular devices market, focusing on the estimation of market size and future growth potential across different segments, including disease pathology, end users, and regions. It also includes a competitive analysis of major market players, highlighting their company profiles, product and service offerings, recent developments, and key market insights strategies.

Reasons to Buy the Report

The report provides valuable insights for both market leaders and new entrants in the diabetes care devices industry, including estimated revenue figures for the overall market and its subsegments. It helps stakeholders understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, helping stakeholders assess the current state of the market.

This report provides insights into the following pointers:

Analysis of key drivers (Rising incidence of neurovascular diseases, Availability of medical reimbursements for neurovascular procedures, Expansion of healthcare infrastructure across emerging economies, Rising demand for effective neurovascular therapies) restraints (Dearth of skilled neurosurgeons, High procedural cost of neurovascular surgeries and associated products), opportunities (Advancement of AI- and robot-assisted systems for next-generation neurointerventions, Growing preference for minimally neurosurgical procedures) and challenges (Stringent regulatory approval process for medical devices).

• Market Penetration: It provides detailed information on the product portfolios offered by major players in the global neurovascular devices market. The report covers various segments, including disease pathology, end user, and regions.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global neurovascular devices market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by disease pathology, end user, and regions.
• Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global neurovascular devices market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global neurovascular devices market.

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 MARKET SCOPE 31
1.3.1 INCLUSIONS AND EXCLUSIONS 31
1.3.2 MARKETS COVERED & REGIONAL SCOPE 32
1.3.3 YEARS CONSIDERED 33
1.4 CURRENCY 33
1.5 LIMITATIONS 34
1.6 SUMMARY OF CHANGES 34
2 EXECUTIVE SUMMARY 35
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 35
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS 36
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 37
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 38
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 39
3 PREMIUM INSIGHTS 40
3.1 NEUROVASCULAR DEVICES MARKET OVERVIEW 40
3.2 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY TYPE AND COUNTRY 41
3.3 NEUROVASCULAR DEVICES MARKET: GEOGRAPHICAL MIX 42
3.4 NEUROVASCULAR DEVICES MARKET: REGIONAL MIX 42
3.5 NEUROVASCULAR DEVICES MARKET: DEVELOPED VS. EMERGING MARKETS 43
4 MARKET OVERVIEW 44
4.1 INTRODUCTION 44
4.2 MARKET DYNAMICS 44
4.2.1 DRIVERS 45
4.2.1.1 Increase in incidence of neurovascular diseases 45
4.2.1.2 Availability of medical reimbursements for neurovascular procedures 45
4.2.1.3 Expansion of healthcare infrastructure across emerging economies 46
4.2.1.4 Rise in demand for effective neurovascular technologies 46
4.2.2 RESTRAINTS 47
4.2.2.1 Dearth of skilled neurosurgeons 47
4.2.2.2 High procedural cost of neurovascular surgeries and associated products 47

4.2.3 OPPORTUNITIES 48
4.2.3.1 Advancement of AI- and robot-assisted systems for next-generation neurointerventions 48
4.2.4 CHALLENGES 48
4.2.4.1 Stringent regulatory approval process for medical devices 48
4.3 UNMET NEEDS AND WHITE SPACES 49
4.3.1 UNMET NEEDS 49
4.3.2 WHITE SPACE OPPORTUNITIES 49
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 49
4.4.1 INTERCONNECTED MARKETS 49
4.4.2 CROSS-SECTOR OPPORTUNITIES 50
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 50
5 INDUSTRY TRENDS 51
5.1 PORTER’S FIVE FORCES ANALYSIS 51
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 52
5.1.2 BARGAINING POWER OF SUPPLIERS 52
5.1.3 BARGAINING POWER OF BUYERS 52
5.1.4 THREAT OF SUBSTITUTES 53
5.1.5 THREAT OF NEW ENTRANTS 53
5.2 MACROECONOMIC OUTLOOK 53
5.2.1 INTRODUCTION 53
5.2.2 GDP TRENDS AND FORECAST 53
5.2.3 TRENDS IN NEUROVASCULAR DEVICES MARKET 55
5.3 SUPPLY CHAIN ANALYSIS 55
5.4 VALUE CHAIN ANALYSIS 57
5.5 ECOSYSTEM ANALYSIS 58
5.6 PRICING ANALYSIS 60
5.6.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY DISEASE PATHOLOGY 60
5.6.2 AVERAGE SELLING PRICE TREND OF NEUROVASCULAR DEVICES, BY REGION 62
5.7 TRADE ANALYSIS 63
5.7.1 IMPORT DATA FOR HS CODE 901890, 2020–2024 63
5.7.2 EXPORT DATA FOR HS CODE 901890, 2020–2024 63
5.8 KEY CONFERENCES & EVENTS, 2025–2026 64
5.9 TRENDS/DISRUPTIONS IMPACTING CONSUMERS’ BUSINESSES 64
5.10 INVESTMENT & FUNDING SCENARIO 65
5.11 CASE STUDY ANALYSIS 66
5.11.1 FLOW DIVERTER FOR COMPLEX INTRACRANIAL ANEURYSMS 66
5.11.2 ADVANCED FLOW DIVERTER WITH ENHANCED DELIVERABILITY 66
5.11.3 STENT RETRIEVER THROMBECTOMY FOR ACUTE IN-STENT THROMBOSIS 66

5.12 IMPACT OF 2025 US TARIFFS ON NEUROVASCULAR DEVICES MARKET 67
5.12.1 INTRODUCTION 67
5.12.2 KEY TARIFF RATES 68
5.12.3 PRICE IMPACT ANALYSIS 68
5.12.4 IMPACT ON COUNTRIES AND REGIONS 69
5.12.4.1 US 69
5.12.4.2 Europe 69
5.12.4.3 Asia Pacific 70
5.12.5 IMPACT ON END-USER INDUSTRIES 70
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS,
AND INNOVATIONS 71
6.1 KEY EMERGING TECHNOLOGIES 71
6.1.1 NEGATIVE PRESSURE CLOT REMOVAL TECHNOLOGY 71
6.2 COMPLEMENTARY TECHNOLOGIES 71
6.2.1 DIGITAL HEALTH AND REMOTE MONITORING PLATFORMS 71
6.3 TECHNOLOGY/PRODUCT ROADMAP 72
6.3.1 SHORT-TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 72
6.3.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 72
6.3.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 73
6.4 PATENT ANALYSIS 73
6.4.1 PATENT PUBLICATION TRENDS FOR NEUROVASCULAR DEVICES MARKET 73
6.4.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN NEUROVASCULAR DEVICES MARKET 74
6.4.3 LIST OF MAJOR PATENTS 75
6.5 IMPACT OF AI/GEN AI ON NEUROVASCULAR DEVICES MARKET 76
6.5.1 TOP USE CASES AND MARKET POTENTIAL 76
6.5.2 TOP CASE STUDIES OF AI IMPLEMENTATION IN NEUROVASCULAR DEVICES MARKET 77
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 77
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NEUROVASCULAR DEVICES MARKET 77
6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 78
6.6.1 RAPID MEDICAL – AI-POWERED ROBOTIC THROMBECTOMY 78
6.6.2 AIDOC – AI IMAGING & STROKE WORKFLOW ACCELERATION 78
6.6.3 RAPIDAI – AI-DRIVEN NEUROVASCULAR IMAGING 78

7 REGULATORY LANDSCAPE 79
7.1 REGIONAL REGULATIONS AND COMPLIANCE 79
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
7.1.2 INDUSTRY STANDARDS 81
7.1.2.1 North America 81
7.1.2.1.1 US 81
7.1.2.1.2 Canada 81
7.1.2.2 Europe 82
7.1.2.3 Asia Pacific 82
7.1.2.3.1 China 82
7.1.2.3.2 Japan 82
7.1.2.3.3 India 82
7.1.2.4 Latin America 82
7.1.2.4.1 Brazil 83
7.1.2.4.2 Mexico 83
7.1.2.5 Middle East 83
7.1.2.6 Africa 83
7.2 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 84
7.2.1 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN NEUROVASCULAR DEVICES MARKET 84
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 85
8.1 DECISION-MAKING PROCESS 85
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 85
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 85
8.2.2 KEY BUYING CRITERIA 86
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 87
8.4 UNMET NEEDS IN END USERS 88
8.5 MARKET PROFITABILITY 89
8.5.1 REVENUE POTENTIAL 89
8.5.2 COST DYNAMICS 89
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 90
9 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY 91
9.1 INTRODUCTION 92
9.2 CEREBRAL ANEURYSMS 92
9.2.1 EMBOLIC COILS 93
9.2.2 BARE DETACHABLE COILS 95
9.2.2.1 Significant adoption of bare detachable coils by neurosurgeons for brain aneurysm treatment to promote growth 95
9.2.3 COATED DETACHABLE COILS 96
9.2.3.1 High cost of coated detachable coils to limit adoption 96
9.2.4 FLOW DIVERSION DEVICES 97
9.2.4.1 Rising R&D activities to develop novel flow diversion devices to promote growth 97
9.2.5 INTRACRANIAL STENTS 98
9.2.5.1 Increased efficacy of stent-assisted coiling for treatment of wide-necked intracranial aneurysms to boost adoption 98
9.2.6 OTHER DEVICES 99
9.3 ISCHEMIC STROKES 100
9.3.1 CLOT RETRIEVER DEVICES 101
9.3.1.1 Proven clinical effectiveness in treating large clots and increase in number of clinical trials aimed at validating their use in ischemic stroke treatment to drive market 101
9.3.2 SUCTION & ASPIRATION DEVICES 102
9.3.2.1 Rapid commercialization of technologically advanced aspiration devices for ischemic stroke treatment to support market 102
9.3.3 VASCULAR SNARES 103
9.3.3.1 Limited procedural benefits in stroke treatment to limit adoption of vascular snares 103
9.3.4 BALLOON CATHETERS 104
9.3.4.1 Growing recognition of benefits associated with balloon catheters to bolster demand 104
9.3.5 OTHER DEVICES 104
9.4 CAROTID ARTERY STENOSIS 105
9.4.1 CAROTID ARTERY STENTS 106
9.4.1.1 Growing adoption of carotid artery stents for carotid intervention procedures to support growth 106
9.4.2 EMBOLIC PROTECTION DEVICES 108
9.4.2.1 Growing utilization of distal filters during carotid intervention procedures to promote growth 108
9.4.3 BALLOON CATHETERS 108
9.4.3.1 Growing preference for balloon catheters to improve efficacy of carotid intervention procedures to augment growth 108
9.5 ARTERIOVENOUS MALFORMATION & FISTULAS 109
9.5.1 LIQUID EMBOLIC AGENTS 110
9.5.1.1 Development of novel liquid embolic agents offering high embolization of arteriovenous fistulas to support growth 110
9.5.2 OCCLUSION BALLOON CATHETERS 111
9.5.2.1 Growing utilization of balloon catheters for AVM treatment to support growth 111
9.5.3 MICROCATHETERS 111
9.5.3.1 Improved compatibility of microcatheters with embolic agents to boost demand 111
9.6 OTHER DISEASE PATHOLOGIES 112

10 NEUROVASCULAR DEVICES MARKET, BY END USER 113
10.1 INTRODUCTION 114
10.2 HOSPITALS AND AMBULATORY SURGICAL CENTERS 114
10.2.1 INCREASING VOLUME OF NEUROVASCULAR PROCEDURES DUE TO AVAILABILITY OF ADVANCED EQUIPMENT TO DRIVE MARKET 114
10.3 SPECIALTY CLINICS 115
10.3.1 INCREASE IN NEUROVASCULAR DISEASES TO DRIVE MARKET 115
10.4 RESEARCH AND ACADEMIC INSTITUTES 116
10.4.1 INCREASING COLLABORATIONS FOR DEVELOPMENT OF TECHNOLOGICALLY ADVANCED NEUROVASCULAR DEVICES TO SUPPORT MARKET GROWTH 116
11 NEUROVASCULAR DEVICES MARKET, BY REGION 117
11.1 INTRODUCTION 118
11.2 NORTH AMERICA 119
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 119
11.2.2 US 123
11.2.2.1 Presence of established neurovascular device manufacturers to drive market 123
11.2.3 CANADA 126
11.2.3.1 Large target pool for ischemic stroke patients to drive market 126
11.3 EUROPE 130
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 130
11.3.2 GERMANY 133
11.3.2.1 Rising geriatric population to drive market 133
11.3.3 FRANCE 136
11.3.3.1 Growing preference for minimally invasive neurovascular procedures to drive market 136
11.3.4 UK 139
11.3.4.1 Rising prevalence of stroke to drive market 139
11.3.5 ITALY 142
11.3.5.1 Increasing geriatric population to drive demand for neurovascular devices 142
11.3.6 SPAIN 145
11.3.6.1 Rising stroke burden and strong healthcare investment to drive demand for neurovascular devices market 145
11.3.7 REST OF EUROPE 148
11.4 ASIA PACIFIC 151
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 152
11.4.2 JAPAN 156
11.4.2.1 Increase in healthcare spending to drive market 156
11.4.3 CHINA 159
11.4.3.1 Robust presence of neurovascular device manufacturers to drive market 159

11.4.4 INDIA 162
11.4.4.1 Increase in prevalence of neurovascular diseases to drive uptake for neurovascular devices 162
11.4.5 AUSTRALIA 165
11.4.5.1 Rise in incidence of cerebrovascular disease to drive market 165
11.4.6 SOUTH KOREA 168
11.4.6.1 Health insurance coverage for neurovascular procedures to support market growth 168
11.4.7 REST OF ASIA PACIFIC 170
11.5 LATIN AMERICA 173
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 173
11.5.2 BRAZIL 176
11.5.2.1 Increasing awareness initiatives on stroke symptoms to drive market 176
11.5.3 MEXICO 179
11.5.3.1 Increasing neurovascular diseases to support market growth 179
11.5.4 REST OF LATIN AMERICA 182
11.6 MIDDLE EAST & AFRICA 185
11.6.1 MACROECONOMIC OUTLOOK FOR THE MIDDLE EAST & AFRICA 185
11.6.2 SHORTAGE OF NEUROSURGEONS AND POOR HEALTHCARE COVERAGE TO RESTRAIN MARKET GROWTH 185
11.6.3 GCC COUNTRIES 189
11.6.3.1 Rising stroke prevalence to drive neurovascular devices market in GCC countries 189
11.6.4 REST OF MIDDLE EAST & AFRICA 192
12 COMPETITIVE LANDSCAPE 196
12.1 INTRODUCTION 196
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 196
12.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET 197
12.3 REVENUE ANALYSIS 198
12.4 MARKET SHARE ANALYSIS, 2024 199
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 202
12.5.1 STARS 202
12.5.2 EMERGING LEADERS 202
12.5.3 PERVASIVE PLAYERS 202
12.5.4 PARTICIPANTS 202
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 204
12.5.5.1 Company footprint 204
12.5.5.2 Regional footprint 205
12.5.5.3 Disease pathology footprint 206
12.5.5.4 By end user footprint 207

12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 208
12.6.1 PROGRESSIVE COMPANIES 208
12.6.2 RESPONSIVE COMPANIES 208
12.6.3 DYNAMIC COMPANIES 208
12.6.4 STARTING BLOCKS 208
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 210
12.6.5.1 Detailed list of key startups/SMEs 210
12.6.5.2 Competitive benchmarking of key startups/SMEs 211
12.7 COMPANY VALUATION & FINANCIAL METRICS 211
12.7.1 FINANCIAL METRICS 211
12.7.2 COMPANY VALUATION 212
12.8 BRAND/PRODUCT COMPARISON 213
12.9 R&D EXPENDITURE OF KEY PLAYERS 214
12.10 COMPETITIVE SCENARIO 214
12.10.1 PRODUCT LAUNCHES AND APPROVALS 214
12.10.2 DEALS 216
12.10.3 EXPANSIONS 217
12.10.4 OTHER DEVELOPMENTS 217
13 COMPANY PROFILES 218
13.1 KEY PLAYERS 218
13.1.1 STRYKER 218
13.1.1.1 Business overview 218
13.1.1.2 Products offered 219
13.1.1.3 Recent developments 224
13.1.1.3.1 Product launches & approvals 224
13.1.1.3.2 Deals 225
13.1.1.3.3 Expansions 226
13.1.1.4 MnM view 226
13.1.1.4.1 Key strengths 226
13.1.1.4.2 Strategic choices 226
13.1.1.4.3 Weaknesses and competitive threats 227
13.1.2 MEDTRONIC 228
13.1.2.1 Business overview 228
13.1.2.2 Products offered 229
13.1.2.3 Recent developments 231
13.1.2.3.1 Product launches & approvals 231
13.1.2.3.2 Expansions 232
13.1.2.4 MnM view 232
13.1.2.4.1 Key strengths 232
13.1.2.4.2 Strategic choices 232
13.1.2.4.3 Weaknesses and competitive threats 232
13.1.3 JOHNSON & JOHNSON 233
13.1.3.1 Business overview 233
13.1.3.2 Products offered 234
13.1.3.3 Recent developments 235
13.1.3.3.1 Product launches & approvals 235
13.1.3.3.2 Other developments 236
13.1.3.4 MnM view 237
13.1.3.4.1 Key strengths 237
13.1.3.4.2 Strategic choices 237
13.1.3.4.3 Weaknesses and competitive threats 237
13.1.4 TERUMO CORPORATION 238
13.1.4.1 Business overview 238
13.1.4.2 Products offered 239
13.1.4.3 Recent developments 240
13.1.4.3.1 Product launches & approvals 240
13.1.4.3.2 Deals 242
13.1.4.3.3 Expansions 242
13.1.4.3.4 Other developments 243
13.1.4.4 MnM view 243
13.1.4.4.1 Key strengths 243
13.1.4.4.2 Strategic choices 243
13.1.4.4.3 Weaknesses and competitive threats 243
13.1.5 PENUMBRA, INC. 244
13.1.5.1 Business overview 244
13.1.5.2 Products offered 245
13.1.5.3 Recent developments 246
13.1.5.3.1 Product launches & approvals 246
13.1.5.4 MnM view 247
13.1.5.4.1 Key strengths 247
13.1.5.4.2 Strategic choices 247
13.1.5.4.3 Weaknesses and competitive threats 247
13.1.6 MICROPORT SCIENTIFIC CORPORATION 248
13.1.6.1 Business overview 248
13.1.6.2 Products offered 249
13.1.6.3 Recent developments 250
13.1.6.3.1 Product launches & approvals 250
13.1.6.4 MnM view 250
13.1.6.4.1 Key strengths 250
13.1.6.4.2 Strategic choices 250
13.1.6.4.3 Weaknesses and competitive threats 251

13.1.7 BALT GROUP 252
13.1.7.1 Business overview 252
13.1.7.2 Products offered 252
13.1.7.3 Recent developments 253
13.1.7.3.1 Deals 253
13.1.7.3.2 Expansions 253
13.1.7.4 MnM view 253
13.1.7.4.1 Key strengths 253
13.1.7.4.2 Strategic choices 254
13.1.7.4.3 Weaknesses and competitive threats 254
13.1.8 KANEKA CORPORATION 255
13.1.8.1 Business overview 255
13.1.8.2 Products offered 256
13.1.8.3 Recent developments 257
13.1.8.3.1 Product launches & approvals 257
13.1.8.3.2 Deals 257
13.1.8.4 MnM view 258
13.1.8.4.1 Key strengths 258
13.1.8.4.2 Strategic choices 258
13.1.8.4.3 Weaknesses and competitive threats 258
13.1.9 PHENOX GMBH (WALLABY MEDICAL) 259
13.1.9.1 Business overview 259
13.1.9.2 Products offered 259
13.1.9.3 Recent developments 260
13.1.9.3.1 Product launches & approvals 260
13.1.9.4 MnM view 260
13.1.9.4.1 Key strengths 260
13.1.9.4.2 Strategic choices 261
13.1.9.4.3 Weaknesses and competitive threats 261
13.1.10 ASAHI INTECC CO., LTD 262
13.1.10.1 Business overview 262
13.1.10.2 Products offered 263
13.1.10.3 Recent developments 264
13.1.10.3.1 Deals 264
13.1.10.3.2 Expansions 264
13.1.10.4 MnM view 265
13.1.10.4.1 Key strengths 265
13.1.10.4.2 Strategic choices 265
13.1.10.4.3 Weaknesses and competitive threats 265

13.1.11 ACHIEVA MEDICAL (PEIJIA MEDICAL) 266
13.1.11.1 Business overview 266
13.1.11.2 Products offered 266
13.1.11.3 Recent developments 267
13.1.11.3.1 Deals 267
13.1.12 RAPID MEDICAL 268
13.1.12.1 Business overview 268
13.1.12.2 Products offered 268
13.1.12.3 Recent developments 269
13.1.12.3.1 Product launches & approvals 269
13.1.12.3.2 Deals 269
13.1.13 JAPAN LIFELINE CO., LTD 270
13.1.13.1 Business overview 270
13.1.13.2 Products offered 271
13.1.14 ACANDIS GMBH 272
13.1.14.1 Business overview 272
13.1.14.2 Products offered 272
13.1.14.3 Recent developments 273
13.1.14.3.1 Expansions 273
13.1.15 EVASC MEDICAL SYSTEM CORP 274
13.1.15.1 Business overview 274
13.1.15.2 Products offered 274
13.1.15.3 Recent developments 274
13.1.15.3.1 Product launches & approvals 274
13.1.15.3.2 Expansions 275
13.2 OTHER KEY PLAYERS 276
13.2.1 SENSOME 276
13.2.2 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. 277
13.2.3 IMPERATIVE CARE, INC. 278
13.2.4 MEDIKIT CO., LTD. 279
13.2.5 ZYLOX-TONBRIDGE MEDICAL CO., LTD. 280
13.3 SMES/STARTUPS 281
13.3.1 NEUROSAFE MEDICAL CO., LTD 281
13.3.2 LUSEED VASCULAR 283
13.3.3 NEUROVASC TECHNOLOGIES, INC. 284
13.3.4 OXFORDENDOVASCULAR 284
13.3.5 GALAXY THERAPEUTICS 285

14 RESEARCH METHODOLOGY 286
14.1 RESEARCH DATA 286
14.1.1 SECONDARY DATA 287
14.1.1.1 Key sources of secondary data 287
14.1.1.2 Key data from secondary sources 288
14.1.2 PRIMARY DATA 288
14.1.2.1 Key primary sources 288
14.1.2.2 Objectives of primary research 289
14.1.2.3 Key data from primary sources 289
14.1.2.4 Key industry insights 290
14.1.2.5 Breakdown of primaries 290
14.2 MARKET SIZE ESTIMATION 291
14.3 DATA TRIANGULATION 297
14.4 MARKET SHARE ESTIMATION 297
14.5 RESEARCH ASSUMPTIONS 298
14.6 FACTOR ANALYSIS 298
14.7 RESEARCH LIMITATIONS 299
14.7.1 SCOPE-RELATED LIMITATIONS 299
14.7.2 METHODOLOGY-RELATED LIMITATIONS 299
14.8 RISK ASSESSMENT 299
14.9 METHODOLOGY-RELATED LIMITATIONS 299
15 APPENDIX 300
15.1 DISCUSSION GUIDE 300
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 303
15.3 CUSTOMIZATION OPTIONS 305
15.4 RELATED REPORTS 305
15.5 AUTHOR DETAILS 306

LIST OF TABLES

TABLE 1 STANDARD CURRENCY CONVERSION RATES 33
TABLE 2 NEUROVASCULAR DEVICES MARKET: UNMET NEEDS 49
TABLE 3 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 50
TABLE 4 NEUROVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES 52
TABLE 5 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021–2030 54
TABLE 6 ROLE IN ECOSYSTEM: NEUROVASCULAR DEVICES MARKET 59
TABLE 7 AVERAGE SELLING PRICE TREND OF STENT RETRIEVERS, BY COMPANY,
2023–2025 (USD) 60
TABLE 8 AVERAGE SELLING PRICE TREND OF CAROTID ARTERY STENTS, BY COMPANY, 2023–2025 (USD) 60
TABLE 9 AVERAGE SELLING PRICE TREND OF ASPIRATION DEVICES, BY COMPANY,
2023–2025 (USD) 61
TABLE 10 AVERAGE SELLING PRICE TREND OF MICROCATHETERS, BY COMPANY,
2023–2025 (USD) 61
TABLE 11 AVERAGE SELLING PRICE TREND OF BALLOON CATHETERS, BY COMPANY,
2023–2025 (USD) 61
TABLE 12 AVERAGE SELLING PRICE TREND OF NEUROVASCULAR DEVICES, BY REGION, 2022–2024 (USD) 62
TABLE 13 IMPORT DATA FOR HS CODE 901890, BY COUNTRY,
2020–2024 (USD THOUSAND) 63
TABLE 14 EXPORT DATA FOR HS CODE 901890, BY COUNTRY,
2020–2024 (USD THOUSAND) 63
TABLE 15 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 64
TABLE 16 MEDTRONIC: FLOW DIVERTER FOR COMPLEX INTRACRANIAL ANEURYSMS 66
TABLE 17 PHENOX: ADVANCED FLOW DIVERTER WITH ENHANCED DELIVERABILITY 66
TABLE 18 STRYKER: STENT RETRIEVER THROMBECTOMY FOR ACUTE IN-STENT THROMBOSIS 66
TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 68
TABLE 20 NEUROVASCULAR DEVICES MARKET: LIST OF MAJOR PATENTS, 2022–2025 75
TABLE 21 TOP USE CASES AND MARKET POTENTIAL 76
TABLE 22 NEUROVASCULAR DEVICES MARKET: CASE STUDIES RELATED TO
GEN AI IMPLEMENTATION 77
TABLE 23 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 77
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 28 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS BY DISEASE PATHOLOGY 86
TABLE 30 KEY BUYING CRITERIA FOR TOP APPLICATIONS 86
TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES 87
TABLE 32 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 92
TABLE 33 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 93
TABLE 34 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 93
TABLE 35 EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION,
2023–2030 (USD MILLION) 94
TABLE 36 EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 94
TABLE 37 EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION,
2023–2030 (THOUSAND UNITS) 95
TABLE 38 BARE DETACHABLE COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 96
TABLE 39 COATED DETACHABLE COILS MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 97
TABLE 40 FLOW DIVERSION DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2023–2030 (USD MILLION) 98
TABLE 41 INTRACRANIAL STENTS MARKET FOR CEREBRAL ANEURYSMS, BY REGION,
2023–2030 (USD MILLION) 98
TABLE 42 INTRACRANIAL STENTS MARKET FOR CEREBRAL ANEURYSMS, BY REGION,
2023–2030 (THOUSAND UNITS) 99
TABLE 43 OTHER DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION,
2023–2030 (USD MILLION) 99
TABLE 44 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION,
2023–2030 (USD MILLION) 100
TABLE 45 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE
2023–2030 (USD MILLION) 101
TABLE 46 CLOT RETRIEVER DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION,
2023–2030 (USD MILLION) 101
TABLE 47 CLOT RETRIEVER DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION,
2023–2030 (THOUSAND UNITS) 102
TABLE 48 SUCTION & ASPIRATION DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 49 VASCULAR SNARES MARKET FOR ISCHEMIC STROKES, BY REGION,
2023–2030 (USD MILLION) 103
TABLE 50 BALLOON CATHETERS MARKET FOR ISCHEMIC STROKES, BY REGION,
2023–2030 (USD MILLION) 104
TABLE 51 OTHER DEVICES MARKET FOR ISCHEMIC STROKES, BY REGION,
2023–2030 (USD MILLION) 105
TABLE 52 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 53 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 106
TABLE 54 CAROTID ARTERY STENTS MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (USD MILLION) 107
TABLE 55 CAROTID ARTERY STENTS MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (THOUSAND UNITS) 107
TABLE 56 EMBOLIC PROTECTION DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY REGION, 2023–2030 (USD MILLION) 108
TABLE 57 BALLOON CATHETERS MARKET FOR CAROTID ARTERY STENOSIS, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 58 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 59 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 110
TABLE 60 LIQUID EMBOLIC AGENTS MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 61 OCCLUSION BALLOON CATHETERS MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 62 MICROCATHETERS MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 63 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES,
BY REGION, 2023–2030 (USD MILLION) 112
TABLE 64 NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 114
TABLE 65 NEUROVASCULAR DEVICES MARKET FOR HOSPITALS AND AMBULATORY SURGICAL CENTERS, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 66 NEUROVASCULAR DEVICES MARKET FOR SPECIALTY CLINICS, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 67 NEUROVASCULAR DEVICES MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 68 NEUROVASCULAR DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 118
TABLE 69 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 70 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 121
TABLE 71 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, 2023–2030 (USD MILLION) 121
TABLE 72 NORTH AMERICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 122
TABLE 73 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 122
TABLE 74 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 122
TABLE 75 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 123
TABLE 76 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 123
TABLE 77 US: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 124
TABLE 78 US: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
2023–2030 (USD MILLION) 124
TABLE 79 US: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 125
TABLE 80 US: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 125
TABLE 81 US: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 125
TABLE 82 US: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 126
TABLE 83 US: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 126
TABLE 84 CANADA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 127
TABLE 85 CANADA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 127
TABLE 86 CANADA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 128
TABLE 87 CANADA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 128
TABLE 88 CANADA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 128
TABLE 89 CANADA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 129
TABLE 90 CANADA: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 129
TABLE 91 EUROPE: NEUROVASCULAR DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 92 EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 131
TABLE 93 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 131
TABLE 94 EUROPE: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 131
TABLE 95 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 132
TABLE 96 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 132
TABLE 97 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 132
TABLE 98 EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 133
TABLE 99 GERMANY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 134
TABLE 100 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 134
TABLE 101 GERMANY: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 134
TABLE 102 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES,
BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 103 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 104 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 105 GERMANY: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 136
TABLE 106 FRANCE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 137
TABLE 107 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 137
TABLE 108 FRANCE: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 138
TABLE 109 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 138
TABLE 110 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 138
TABLE 111 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 139
TABLE 112 FRANCE: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 139
TABLE 113 UK: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 140
TABLE 114 UK: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 140
TABLE 115 UK: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 141
TABLE 116 UK: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 117 UK: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 118 UK: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 119 UK: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 142
TABLE 120 ITALY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 143
TABLE 121 ITALY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 143
TABLE 122 ITALY: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 143
TABLE 123 ITALY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 144
TABLE 124 ITALY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 144
TABLE 125 ITALY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 144
TABLE 126 ITALY: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 145
TABLE 127 SPAIN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 146
TABLE 128 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 146
TABLE 129 SPAIN: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 146
TABLE 130 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 147
TABLE 131 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 147
TABLE 132 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 147
TABLE 133 SPAIN: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 148
TABLE 134 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 149
TABLE 135 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 136 REST OF EUROPE: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 137 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 138 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 139 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 140 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 151
TABLE 141 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 142 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 153
TABLE 143 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 144 ASIA PACIFIC: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 145 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES,
BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 146 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 155
TABLE 147 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 155
TABLE 148 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 155
TABLE 149 JAPAN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 156
TABLE 150 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 157
TABLE 151 JAPAN: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 152 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 157
TABLE 153 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 154 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 155 JAPAN: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 158
TABLE 156 CHINA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 159
TABLE 157 CHINA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 158 CHINA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 160
TABLE 159 CHINA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 160 CHINA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 161 CHINA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 162 CHINA: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 161
TABLE 163 INDIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 162
TABLE 164 INDIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 163
TABLE 165 INDIA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 163
TABLE 166 INDIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 163
TABLE 167 INDIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 168 INDIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 169 INDIA: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 164
TABLE 170 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 165
TABLE 171 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 172 AUSTRALIA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 173 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES,
BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 174 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 175 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 176 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 167
TABLE 177 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 168
TABLE 178 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 179 SOUTH KOREA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 180 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES,
BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 181 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 182 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 183 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 170
TABLE 184 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET,
BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 171
TABLE 185 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 171
TABLE 186 REST OF ASIA PACIFIC: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 171
TABLE 187 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 188 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 189 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 190 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 173
TABLE 191 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 174
TABLE 192 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 174
TABLE 193 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 194 LATIN AMERICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 195 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES,
BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 196 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 197 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 176
TABLE 198 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 176
TABLE 199 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 177
TABLE 200 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 177
TABLE 201 BRAZIL: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 178
TABLE 202 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 203 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 204 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 205 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY END USER
2023–2030 (USD MILLION) 179
TABLE 206 MEXICO: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2023–2030 (USD MILLION) 180
TABLE 207 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS,
BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 208 MEXICO: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE,
2023–2030 (USD MILLION) 180
TABLE 209 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 210 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS,
BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 211 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 212 MEXICO: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 182
TABLE 213 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET,
BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 182
TABLE 214 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 183
TABLE 215 REST OF LATIN AMERICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 183
TABLE 216 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 183
TABLE 217 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 218 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE,
2023–2030 (USD MILLION) 184
TABLE 219 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 184
TABLE 220 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY SUBREGION, 2023–2030 (USD MILLION) 186
TABLE 221 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET,
BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 186
TABLE 222 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 187
TABLE 223 MIDDLE EAST & AFRICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 187
TABLE 224 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 187
TABLE 225 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 226 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE,
2023–2030 (USD MILLION) 188
TABLE 227 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 188
TABLE 228 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 190
TABLE 229 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 230 GCC COUNTRIES: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 231 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 232 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 233 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 234 GCC COUNTRIES: NEUROVASCULAR DEVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 192
TABLE 235 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET,
BY DISEASE PATHOLOGY, 2023–2030 (USD MILLION) 193
TABLE 236 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 237 REST OF MIDDLE EAST & AFRICA: EMBOLIC COILS MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 238 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 239 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 240 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE,
2023–2030 (USD MILLION) 194
TABLE 241 REST OF MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 195
TABLE 242 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET, JANUARY 2022–JUNE 2025 197
TABLE 243 NEUROVASCULAR DEVICE MARKET: DEGREE OF COMPETITION 200
TABLE 244 NEUROVASCULAR DEVICES MARKET: REGIONAL FOOTPRINT, 2024 205
TABLE 245 NEUROVASCULAR DEVICES MARKET: DISEASE PATHOLOGY FOOTPRINT, 2024 206
TABLE 246 NEUROVASCULAR DEVICES MARKET: BY END USER FOOTPRINT 207
TABLE 247 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS, 2024 210
TABLE 248 NEUROVASCULAR DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT TYPE AND REGION, 2024 211
TABLE 249 NEUROVASCULAR DEVICES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–NOVEMBER 2025 214
TABLE 250 NEUROVASCULAR DEVICES MARKET: DEALS, JANUARY 2022–NOVEMBER 2025 216
TABLE 251 NEUROVASCULAR DEVICES MARKET: EXPANSIONS,
JANUARY 2022–NOVEMBER 2025 217
TABLE 252 NEUROVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–NOVEMBER 2025 217
TABLE 253 STRYKER: COMPANY OVERVIEW 218
TABLE 254 STRYKER: PRODUCTS OFFERED 219
TABLE 255 STRYKER: PRODUCT LAUNCHES & APPROVALS 224
TABLE 256 STRYKER: DEALS 225
TABLE 257 STRYKER: EXPANSIONS 226
TABLE 258 MEDTRONIC: COMPANY OVERVIEW 228
TABLE 259 MEDTRONIC: PRODUCTS OFFERED 229
TABLE 260 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS 231
TABLE 261 MEDTRONIC: EXPANSIONS 232
TABLE 262 JOHNSON & JOHNSON: BUSINESS OVERVIEW 233
TABLE 263 JOHNSON & JOHNSON: PRODUCTS OFFERED 234
TABLE 264 JOHNSON & JOHNSON: PRODUCT LAUNCHES & APPROVALS 235
TABLE 265 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS 236
TABLE 266 TERUMO CORPORATION: COMPANY OVERVIEW 238
TABLE 267 TERUMO CORPORATION: PRODUCTS OFFERED 239
TABLE 268 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS 240
TABLE 269 TERUMO CORPORATION: DEALS 242
TABLE 270 TERUMO CORPORATION: EXPANSIONS 242
TABLE 271 TERUMO CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 243
TABLE 272 PENUMBRA, INC.: COMPANY OVERVIEW 244
TABLE 273 PENUMBRA, INC.: PRODUCTS OFFERED 245
TABLE 274 PENUMBRA, INC.: PRODUCT LAUNCHES & APPROVALS 246
TABLE 275 MICROPORT SCIENTIFIC CORPORATION: COMPANY OVERVIEW 248
TABLE 276 MICROPORT SCIENTIFIC CORPORATION: PRODUCTS OFFERED 249
TABLE 277 MICROPORT SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS 250
TABLE 278 BALT GROUP: COMPANY OVERVIEW 252
TABLE 279 BALT GROUP: PRODUCTS OFFERED 252
TABLE 280 BALT GROUP: DEALS 253
TABLE 281 BALT GROUP: EXPANSIONS 253
TABLE 282 KANEKA CORPORATION: COMPANY OVERVIEW 255
TABLE 283 KANEKA CORPORATION: PRODUCTS OFFERED 256
TABLE 284 KANEKA CORPORATION: PRODUCT LAUNCHES & APPROVALS 257
TABLE 285 KANEKA CORPORATION: DEALS 257
TABLE 286 PHENOX GMBH (WALLABY MEDICAL): COMPANY OVERVIEW 259
TABLE 287 PHENOX GMBH (WALLABY MEDICAL): PRODUCTS OFFERED 259
TABLE 288 PHENOX GMBH (WALLABY MEDICAL): PRODUCT LAUNCHES & APPROVALS 260
TABLE 289 ASAHI INTECC CO., LTD.: COMPANY OVERVIEW 262
TABLE 290 ASAHI INTECC CO., LTD.: PRODUCTS OFFERED 263
TABLE 291 ASAHI INTECC CO., LTD: DEALS 264
TABLE 292 ASAHI INTECC CO., LTD: EXPANSIONS 264
TABLE 293 ACHIEVA MEDICAL (PEIJIA MEDICAL): COMPANY OVERVIEW 266
TABLE 294 ACHIEVA MEDICAL (PEIJIA MEDICAL): PRODUCTS OFFERED 266
TABLE 295 ACHIEVA MEDICAL (PEIJIA MEDICAL): DEALS 267
TABLE 296 RAPID MEDICAL: COMPANY OVERVIEW 268
TABLE 297 RAPID MEDICAL: PRODUCTS OFFERED 268
TABLE 298 RAPID MEDICAL: PRODUCT LAUNCHES & APPROVALS 269
TABLE 299 RAPID MEDICAL: DEALS 269
TABLE 300 JAPAN LIFELINE CO., LTD: COMPANY OVERVIEW 270
TABLE 301 JAPAN LIFELINE CO., LTD: PRODUCTS OFFERED 271
TABLE 302 ACANDIS GMBH: COMPANY OVERVIEW 272
TABLE 303 ACANDIS GMBH: PRODUCTS OFFERED 272
TABLE 304 ACANDIS GMBH: EXPANSIONS 273
TABLE 305 EVASC MEDICAL SYSTEM CORP: COMPANY OVERVIEW 274
TABLE 306 EVASC MEDICAL SYSTEM CORP: PRODUCTS OFFERED 274
TABLE 307 EVASC MEDICAL SYSTEM CORP: PRODUCT LAUNCHES & APPROVALS 274
TABLE 308 EVASC MEDICAL SYSTEM CORP: EXPANSIONS 275
TABLE 309 RESEARCH ASSUMPTIONS 298
TABLE 310 RISK ASSESSMENT 299

LIST OF FIGURES

FIGURE 1 MARKETS COVERED & REGIONAL SCOPE 32
FIGURE 2 YEARS CONSIDERED 33
FIGURE 3 MARKET SCENARIO 35
FIGURE 4 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY,
2025 VS. 2030 (USD MILLION) 36
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET 36
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF NEUROVASCULAR DEVICES MARKET 37
FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN NEUROVASCULAR DEVICES MARKET, 2024 38
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 39
FIGURE 9 INCREASE IN NUMBER OF DISEASES RELATED TO NEUROLOGICAL DISORDERS SUCH AS CEREBRAL ANEURYSMS AND STROKES TO DRIVE MARKET GROWTH 40
FIGURE 10 CEREBRAL ANEURYSMS SEGMENT ACCOUNTED FOR HIGHEST MARKET SHARE
IN ASIA PACIFIC 41
FIGURE 11 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 42
FIGURE 12 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD, 2025–2030 42
FIGURE 13 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 43
FIGURE 14 DIABETES CARE DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 44
FIGURE 15 NEUROVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 51
FIGURE 16 NEUROVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS 56
FIGURE 17 NEUROVASCULAR DEVICES MARKET: VALUE CHAIN ANALYSIS 57
FIGURE 18 NEUROVASCULAR DEVICES MARKET: ROLE IN ECOSYSTEM 59
FIGURE 19 NEUROVASCULAR DEVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 65
FIGURE 20 NEUROVASCULAR DEVICES MARKET: FUNDING (USD MILLION) AND
NUMBER OF DEALS, 2019–2023 65
FIGURE 21 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR NEUROVASCULAR DEVICES MARKET, JANUARY 2014–DECEMBER 2024 74
FIGURE 22 TOP PATENT APPLICANT COUNTRIES FOR NEUROVASCULAR DEVICES MARKET, JANUARY 2014–DECEMBER 2024 75
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
BY DISEASE PATHOLOGY 85
FIGURE 24 KEY BUYING CRITERIA, BY DISEASE PATHOLOGY 86
FIGURE 25 NEUROVASCULAR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 119
FIGURE 26 NEUROVASCULAR DEVICES MARKET: NORTH AMERICA SNAPSHOT 120
FIGURE 27 NEUROVASCULAR DEVICES MARKET: ASIA PACIFIC SNAPSHOT 152
FIGURE 28 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET, 2022–2024 (USD MILLION) 199
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NEUROVASCULAR DEVICES MARKET, 2024 199
FIGURE 30 NEUROVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 203
FIGURE 31 NEUROVASCULAR DEVICES MARKET: COMPANY FOOTPRINT, 2024 204
FIGURE 32 NEUROVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 209
FIGURE 33 EV/EBITDA OF KEY VENDORS, 2024 211
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 212
FIGURE 35 NEUROVASCULAR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 213
FIGURE 36 NEUROVASCULAR DEVICES MARKET: R&D EXPENDITURE OF KEY PLAYERS,
2022–2024 214
FIGURE 37 STRYKER: COMPANY SNAPSHOT, 2024 219
FIGURE 38 MEDTRONIC: COMPANY SNAPSHOT, 2024 229
FIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT, 2024 234
FIGURE 40 TERUMO CORPORATION: COMPANY SNAPSHOT, 2024 239
FIGURE 41 PENUMBRA, INC.: COMPANY SNAPSHOT, 2024 245
FIGURE 42 MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT, 2024 249
FIGURE 43 KANEKA CORPORATION: COMPANY SNAPSHOT, 2024 256
FIGURE 44 ASAHI INTECC CO., LTD: COMPANY SNAPSHOT, 2024 263
FIGURE 45 JAPAN LIFELINE CO., LTD: COMPANY SNAPSHOT, 2024 270
FIGURE 46 RESEARCH DESIGN 286
FIGURE 47 NEUROVASCULAR DEVICES MARKET: KEY DATA FROM SECONDARY SOURCES 288
FIGURE 48 NEUROVASCULAR DEVICES MARKET: KEY PRIMARY SOURCES
(DEMAND AND SUPPLY SIDE) 288
FIGURE 49 KEY DATA FROM PRIMARY SOURCES 289
FIGURE 50 KEY INSIGHTS FROM INDUSTRY EXPERTS 290
FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 290
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS, BY END USER, DESIGNATION,
AND REGION 291
FIGURE 53 MARKET SIZE ESTIMATION PROCESS THROUGH REVENUE DATA 292
FIGURE 54 US: REVENUE SHARE ANALYSIS FOR STRYKER, 2024 292
FIGURE 55 SUPPLY SIDE ANALYSIS, 2024 293
FIGURE 56 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 293
FIGURE 57 BOTTOM-UP APPROACH 294
FIGURE 58 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES ANALYSIS, 2025–2030 295
FIGURE 59 TOP-DOWN APPROACH 296
FIGURE 60 DATA TRIANGULATION METHODOLOGY 297
FIGURE 61 FACTOR ANALYSIS 298

---

---